Identification and validation of stage-specific microRNAs and target genes for prostate cancer: Utilizing bioinformatics tools for diagnostic marker discovery.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Prostatic Neoplasms*/genetics ; Prostatic Neoplasms*/diagnosis ; Prostatic Neoplasms*/pathology ; MicroRNAs*/genetics ; MicroRNAs*/metabolism ; Biomarkers, Tumor*/genetics ; Computational Biology*/methods; Humans ; Male ; Gene Expression Regulation, Neoplastic ; Middle Aged ; Gene Regulatory Networks ; Aged ; Neoplasm Staging

Given the urgent need for more specific, sensitive, and non-invasive markers for prostate cancer screening and differential diagnosis, circulating miRNAs have emerged as valuable candidates. Sixty seven prostate cancer subjects in different stages were included in this study. The participants were categorized into groups based on their pathological characteristics as local, biochemical relapse and metastatic. We retrieved eligible datasets from GEO database to identify stage-specific differentially expressed up/down-regulated genes. Cytohubba, built-in application of Cytoscape software, and Reactome pathway database were applied to select hub genes. To select upstream miRNAs, we utilized the MiRWalk and miRNet online tools. To construct the miRNA-mRNA regulatory networks, we employed rna22. Finally, three miRNAs and five target genes were validated in peripheral blood mononuclear cells of PCa patients compared with benign prostate hyperplasia. PSA level was also measured using ELISA. Our findings revealed the potential role of PRC1 and UBA52 to be used as biomarkers for the metastatic stage, RCC1 for both biochemical relapse, and metastatic subjects. Furthermore, elevated levels of miR-124-3p and downregulation of miR-133a-3p can be introduced as biochemical relapse stage identifier. We also identified the tumor suppressor role of miR-17-5p, which was associated with higher Gleason scores. We propose PRC1, UBA52, RCC1, miR-124-3p and miR133a-3p as stage-specific PCa identifiers.
(Copyright: © 2025 Yaghobinejad et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

There is no competing interest.

PLoS One. 2019 Nov 22;14(11):e0224071. (PMID: 31756185)
Prostate. 2022 Feb;82(2):193-202. (PMID: 34662930)
Cancer Cell. 2019 Aug 12;36(2):117-119. (PMID: 31408617)
BMC Med Genet. 2019 Dec 2;20(1):191. (PMID: 31791268)
Biochem Biophys Res Commun. 2018 Mar 25;498(1):38-44. (PMID: 29371016)
Oncol Lett. 2021 Sep;22(3):649. (PMID: 34386071)
J Clin Lab Anal. 2020 Feb;34(2):e23063. (PMID: 31595567)
Biomed Res Int. 2018 Jun 20;2018:6204128. (PMID: 30027097)
Oncotarget. 2018 Jun 5;9(43):27256-27267. (PMID: 29930763)
Cancer Epidemiol Biomarkers Prev. 2024 Feb 6;33(2):186-195. (PMID: 38317630)
J Biol Res (Thessalon). 2015 Oct 22;22:12. (PMID: 26500892)
Ther Adv Med Oncol. 2019 May 08;11:1758835919846375. (PMID: 31156720)
Front Mol Biosci. 2022 Feb 15;9:858514. (PMID: 35242815)
Oncol Lett. 2021 Jun;21(6):457. (PMID: 33907567)
Biomed Res Int. 2022 Mar 20;2022:6319685. (PMID: 35355828)
Bioinform Biol Insights. 2022 Aug 6;16:11779322221115545. (PMID: 35958298)
Kaohsiung J Med Sci. 2024 Jan;40(1):23-34. (PMID: 37916740)
J Cell Commun Signal. 2023 Sep;17(3):423-443. (PMID: 36367667)
Aging (Albany NY). 2020 May 19;12(10):8880-8892. (PMID: 32428870)
Cancer Cell Int. 2020 Feb 05;20:40. (PMID: 32042267)
J Clin Lab Anal. 2020 Jul;34(7):e23266. (PMID: 32125723)
J Cell Biochem. 2019 Sep;120(9):15963-15970. (PMID: 31081222)
Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1064-8. (PMID: 9037006)
Endocr Metab Immune Disord Drug Targets. 2023;23(14):1699-1712. (PMID: 36872354)
J Exp Clin Cancer Res. 2018 Dec 20;37(1):320. (PMID: 30572959)
Pathol Res Pract. 2019 Jun;215(6):152375. (PMID: 30879885)
Int J Cancer. 2018 Jun 15;142(12):2512-2517. (PMID: 29363114)
Front Oncol. 2023 May 08;13:1142275. (PMID: 37251950)
Urol Oncol. 2020 Jul;38(7):623-635. (PMID: 32284256)
PLoS One. 2013 Oct 22;8(10):e76994. (PMID: 24167554)
Sci Rep. 2017 Nov 7;7(1):14671. (PMID: 29116087)
Oncol Lett. 2018 Jan;15(1):984-990. (PMID: 29387242)
Int J Mol Sci. 2016 Dec 09;17(12):. (PMID: 27941681)
J Exp Clin Cancer Res. 2019 Nov 27;38(1):478. (PMID: 31775888)
Int J Oncol. 2020 Mar;56(3):685-696. (PMID: 31922238)
Eur J Med Res. 2014 Sep 03;19:47. (PMID: 25183411)
Oxid Med Cell Longev. 2021 Aug 31;2021:8846951. (PMID: 34512870)
Oncogene. 2013 Jun 13;32(24):2973-83. (PMID: 22890325)
EMBO J. 2018 Dec 3;37(23):. (PMID: 30389667)
Trends Cancer. 2018 Jan;4(1):59-73. (PMID: 29413422)
Biochem Soc Trans. 2022 Feb 28;50(1):83-93. (PMID: 35191966)
Cancer Manag Res. 2021 Sep 21;13:7263-7276. (PMID: 34584453)
Biomark Res. 2022 Apr 8;10(1):19. (PMID: 35395937)
J Clin Oncol. 2008 Mar 1;26(7):1148-59. (PMID: 18309951)
Clin Transl Med. 2022 Mar;12(3):e694. (PMID: 35352511)
J Clin Invest. 2020 Apr 1;130(4):1743-1751. (PMID: 31874108)
Actas Urol Esp (Engl Ed). 2022 Apr;46(3):138-149. (PMID: 35260368)
Mol Cell Biol. 2012 Oct;32(20):4237-44. (PMID: 22907752)
Oncogene. 2013 Aug 29;32(35):4130-8. (PMID: 23069658)
Oncotarget. 2017 Jul 18;8(41):71206-71222. (PMID: 29050357)
Front Mol Biosci. 2020 Sep 15;7:225. (PMID: 33102517)
Cancer Biomark. 2019;24(2):159-172. (PMID: 30614803)
J Exp Clin Cancer Res. 2018 Jul 18;37(1):160. (PMID: 30021600)
Biomed Pharmacother. 2016 Mar;78:116-120. (PMID: 26898432)
Microrna. 2020;9(2):82-92. (PMID: 31538910)
Front Oncol. 2020 Oct 08;10:536875. (PMID: 33134160)

0 (MicroRNAs)
0 (Biomarkers, Tumor)

Date Created: 20251104 Date Completed: 20251104 Latest Revision: 20251107

20260130

PMC12585097

10.1371/journal.pone.0315366

41187218